Alteplase for acute ischemic stroke: Outcomes by clinically important subgroups in the Third International Stroke Trial

Stroke

Volumn 46, Issue 3, 2015, Pages 746-756

  Lindley, Richard I ^a   Wardlaw, Joanna M ^b   Whiteley, William N ^b   Cohen, Geoff ^b   Blackwell, Lisa ^c   Murray, Gordon D ^b   Sandercock, Peter A G ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Alteplase; Intracranial hemorrhages; Stroke; Thrombolytic therapy; Treatment outcome

Indexed keywords

ALTEPLASE; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGE DISTRIBUTION; AGED; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VERY ELDERLY; ADOLESCENT; ADULT; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; INTERNATIONAL COOPERATION; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STROKE; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONAL COOPERATION; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929294516     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006573     Document Type: Article

References (25)

1. Sandercock PAG, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al; International Stroke Trial Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [ist-3]): a randomised controlled trial. Lancet. 2012;379:2352-2363. doi: 10.1016/S0140-6736 (12) 60768-5.
2. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379:2364-2372. doi: 10.1016/S0140-6736 (12) 60738-7.
3. Sandercock P, Wardlaw JM, Dennis M, Cohen G, Murray G, Innes K, et al. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third international stroke trial ist-3): 18-month follow-up of a randomised controlled trial. Lancet Neurology. 2013;12:768-776. doi: 10.1016/S1474-4422 (13) 70130-3.
4. Whiteley W, Lindley R, Wardlaw J, Sandercock P; IST-3 Collaborative Group. Third international stroke trial. Int J Stroke. 2006;1:172-176. doi: 10.1111/j.1747-4949.2006.00043.x.
5. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al; European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012;43:1171-1178. doi: 10.1161/STROKEAHA.111.641456.
6. McHugh GS, Butcher I, Steyerberg EW, Marmarou A, Lu J, Lingsma HF, et al. A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project. Clin Trials. 2010;7:44-57. doi: 10.1177/1740774509356580.
7. Roozenbeek B, Lingsma HF, Perel P, Edwards P, Roberts I, Murray GD, et al; IMPACT (International Mission on Prognosis and Clinical Trial Design in Traumatic Brain Injury) Study Group; CRASH (Corticosteroid Randomisation After Significant Head Injury) Trial Collaborators. The added value of ordinal analysis in clinical trials: an example in traumatic brain injury. Crit Care. 2011;15:R127. doi: 10.1186/cc10240.
8. Weir J, Steyerberg EW, Butcher I, Lu J, Lingsma HF, McHugh GS, et al. Does the extended Glasgow Outcome Scale add value to the conventional Glasgow Outcome Scale? J Neurotrauma. 2012;29:53-58. doi: 10.1089/neu.2011.2137.
9. Maas AI, Murray GD, Roozenbeek B, Lingsma HF, Butcher I, McHugh GS, et al; International Mission on Prognosis Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) Study Group. Advancing care for traumatic brain injury: findings from the IMPACT studies and perspectives on future research. Lancet Neurol. 2013;12:1200-1210. doi: 10.1016/S1474-4422 (13) 70234-5.
10. Sandercock P, Lindley R, Wardlaw J, Dennis M, Lewis S, Venables G, et al; IST-3 Collaborative Group. Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials. 2008;9:37. doi: 10.1186/1745-6215-9-37.
11. Sandercock P, Lindley R, Wardlaw J, Whiteley W, Murray G; ST-3 collaborative group. Statistical analysis plan for the third International Stroke Trial (IST-3); part of a 'thread' of reports of the trial. Int J Stroke. 2012;7:186-187. doi: 10.1111/j.1747-4949.2012.00782.x.
12. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
13. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25:2220-2226.
14. Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet. 2005;365:1657-1661. doi: 10.1016/S0140-6736 (05) 66516-6.
15. Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, et al; IST-3 collaborative group. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials. 2011;12:252. doi: 10.1186/1745-6215-12-252.
16. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
17. NINDS t-PA Study Group. Generalized efficacy of t-pa for acute stroke. Subgroup analysis of the ninds t-pa stroke trial. Stroke. 1997;28:2119-2125
18. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, et al; NINDS r-tPA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS r-tPA Stroke Trial. Neurology. 2002;59:669-674.
19. Lindley RI, Wardlaw JM, Sandercock PA, Rimdusid P, Lewis SC, Signorini DF, et al. Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis. 2004;13:235-246. doi: 10.1016/j.jstrokecerebrovasdis.2004.03.003.
20. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43:2904-2909. doi: 10.1161/STROKEAHA.112.665331.
21. Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A, et al; VISTA Collaborators. Thrombolysis in stroke despite contraindications or warnings? Stroke. 2013;44:727-733. doi: 10.1161/STROKEAHA.112.674622.
22. Mishra NK, Ahmed N, Davalos A, Iversen HK, Melo T, Soinne L, et al; SITS and VISTA collaborators. Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology. 2011;77:1866-1872. doi: 10.1212/WNL.0b013e318238ee42.
23. Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA, et al; VISTA collaborators; SITS collaborators. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ. 2010;341:c6046.
24. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929-1935. doi: 10.1016/S0140-6736 (14) 60584-5.
25. Lyden PD. In anticipation of International Stroke Trial-3 (IST-3). Stroke. 2012;43:1691-1694. doi: 10.1161/STROKEAHA.112.656876.